Initiate a Phase 3 trial of ACP-101 for Prader-Willi syndrome
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 2 Aug 2023
- Due
- 31 Dec 2023
- Delivered
- November 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“In the fourth quarter of this year, we will initiate a Phase 3 trial of ACP-101 for Prader-Willi syndrome”
What we found
Evidence strength A What the grades mean
The company initiated the Phase 3 COMPASS PWS study of ACP-101 in November 2023, which falls within the fourth quarter of 2023.
-
A Acadia Pharmaceuticals Inc. 10-K filed 2024-02-28
“In November 2023, we initiated the Phase 3 COMPASS PWS study evaluating the efficacy and safety of ACP-101 for the treatment of hyperphagia in PWS.” ✓ confirmed on the page
Market reaction: the shares moved -10.1% against the S&P 500 over the three sessions around the disclosure (27 Feb 2024 to 1 Mar 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Language weakened: firm → expected
- 2 versions
-
Version 1 · original · stated 2 Aug 2023
Deadline 31 Dec 2023 (“fourth quarter of this year”) · wording firm
-
Version 2 · stated 2 Nov 2023
Deadline 31 Dec 2023 (“in the fourth quarter of 2023”) · wording expected
“The Company plans to initiate a Phase 3 placebo-controlled study of ACP-101 for the treatment of hyperphagia in Prader-Willi syndrome in the fourth quarter of 2023.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 3 trial of ACP-101
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Acadia Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-ACAD-002584 · Corrections policy